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Characterization of Metronidazole- and Vancomycin-Resistant Clinical Isolates of
Clostridium difficile
Chioma Odo, MS.
Supervisory Professor: Charles Darkoh, Ph.D.
ABSTRACT
The incidence of C. difficile infections (CDI) has been increasing at an alarming rate. This
was precipitated by the emergence of strains with increased virulence, disease severity,
and high recurrence rates. These strains also exhibit high propensity for resistance to
antibiotics such as fluoroquinolones and beta lactams, which has made the treatment of
CDI very challenging. Currently, metronidazole and vancomycin are the most commonly
used drugs for the treatment of primary CDI. Metronidazole is used for the treatment of
mild to non-severe cases of CDI while vancomycin is reserved for severe CDI cases. In
25-30% of the patients treated with these antibiotics, the infection may recur, and this
further complicates CDI treatment. Because C. difficile strains have an intrinsic ability to
resist multiple antibiotics, it was hypothesized that there may be strains with high
resistance to metronidazole and vancomycin circulating in the patient population. To
investigate this hypothesis, 536 clinical CDI stool samples obtained from patients who
presented with diarrhea at St. Luke’s Episcopal Hospital at the Texas Medical Center
Houston, Texas, Kenyatta National Hospital, Nairobi, and Kisii Teaching and Referral
Hospital, Kisii, Kenya were screened for resistant C. difficile strains. The stool samples
were analyzed on C. difficile-specific differential medium containing either metronidazole
(8 µg/ml) or vancomycin (4 µg/ml). These are concentrations designated by the Clinical
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and Laboratory Standards Institute to be the resistant breakpoint for each of the
antibiotics. Stools that grew resistant colonies were identified and colonies were selected
for further analysis. The minimum inhibitory concentration (MIC) of the isolates was
determined by E-test and broth microdilution. The results showed that 33.1% (145/438)
of the CDI patients from Texas had C. difficile strains in their stools that were resistant to
both metronidazole and vancomycin. Remarkably, 93.9% of the CDI patient stools from
Kenya had both metronidazole- and vancomycin-resistant C. difficile strains. The resistant
strains from both patient populations also exhibit high level of tolerance for these
antibiotics that far exceed the previously reported MICs (˃1024 µg/ml compared to 256
µg/ml for metronidazole and >1024 µg/ml compared to 16 µg/ml for vancomycin). All of
the vancomycin-resistant strains isolated from the patients in both populations had the
homologue of vanA gene, which has been shown to confer a high degree of vancomycin
resistance in Gram-positive bacteria. Together, the results demonstrate high prevalence
of metronidazole- and vancomycin-resistant C. difficile strains circulating in the patient
populations from Texas and Kenya. The spread of C. difficile strains that are resistant to
these two antibiotics of last resort may have serious public health implications and
underscores the urgent need for a more in-depth analysis of the circulating resistant
strains to help inform clinical decisions.
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INTRODUCTION
Epidemiology of Clostridium difficile Infections
Clostridium difficile is a multidrug-resistant, spore forming, Gram-positive
anaerobic pathogen. It is the most common cause of hospital-acquired and healthcareassociated infectious diarrhea (1). Broad spectrum antibiotics use is the most common
risk factor for Clostridium difficile infection (CDI), as it alters colonization resistance,
thereby rendering the microbiota susceptible to C. difficile colonization and infection (2).
Clinical symptoms of CDI range from mild to severe diarrhea, pseudomembranous
colitis, toxin megacolon, septic shock or even death (3). The Centers for Disease
Control and Prevention (CDC) has classified C. difficile as an urgent threat with
approximately 453,000 reported cases, 29,000 deaths, and $1.1 to 7 billion in treatment
costs annually in the US (4). Recently, the incidence of CDI has exceeded that of
methicillin-resistant Staphylococcus aureus (MRSA) in the community hospitals (5).
There is an increased report of CDI among the young under 18 and also in communities
outside the hospital, such as assisted care facilities for the elderly.
The emergence of C. difficile strains with resistance to multiple antibiotics,
especially the most prominent hyper-virulent strain ribotype (RT) 027, has added
another complication to the treatment of CDI (6). (RT) 027, which is commonly found in
the US, Europe and Canada is completely intractable to traditional treatment with
increased recurrence and mortality rate (6). The emergence is associated with
fluoroquinolone exposure (6). C. difficile RT027, also known as fluoroquinoloneresistant (FQR) C. difficile, is the most common cause of outbreaks in North America
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and the UK (with more than 40% of the reported cases in the UK) and it was recently
reported to be common in other parts of Europe and Australia (7).

Clostridium difficile Pathogenesis
C. difficile is spread through ingestion of its spores, which tolerates both stomach
acidic and harsh environmental conditions. Under favorable conditions, such as the
presence of bile acids in the small intestine, the ingested spores germinate into
vegetative cells that colonize the large intestine following disruption of normal
microbiota by antibiotic therapy (15).
Spore germination is initiated when a receptor within the inner membrane of the
spore interacts with a germinant such as ions, sugar, nucleotides, bile acids or
surfactants (48). When the spore receptor senses or recognizes a germinant, it triggers
an irreversible spore germination process which leads to the release of Ca 2+-dipicolinic
acid, water uptake, spore cortex degradation, and outgrowth of the vegetative cells and
under appropriate conditions, produce toxins that cause disease (41).
The vegetative form of C. difficile thrives in the lumen of the large intestine and
produces two major toxins: toxins A (an enterotoxin) and B (a cytotoxin) (15). These two
major virulence factors are encoded by the tcdA and tcdB genes, respectively, and are
located within 19.6 kb of the pathogenicity locus (PaLoc) in the genome (Fig.1). They are
members of large clostridial toxins, a family of toxins that modifies GTPases (16, 95, 96).
Also found in the pathogenicity locus is tcdC, which negatively regulates expression of
tcdA and tcdB. The tcdE gene, encodes a holin (essential for the extracellular release of
2

toxins A and B) and tcdR, encodes a sigma factor that is required for toxin A and B
expression. The PaLoc, located at the same site in all toxin-producing strains, can be
horizontally transferred to non-toxin producing strains, however, it is not intrinsically
mobile (38).
The amino acid sequences of TcdA and TcdB are 44% identical and 66% similar
and share a common structure (95). The C-terminus has a high degree of sequence
diversity. Both toxins have a similar three-dimensional structure and a similar mode of
entry into host cells (38). They both have a “pincher-like” head delivery domain, a
receptor-binding domain, also known as the long tail domain at the C-terminus, and a
short inner tailed (52) glucosyltransferase domain at the N-terminus. Generally, both
toxins share similar enzymatic activities, as well as multi-modular domain structure,
described as the ABCD model (A: biological activity, B: binding, C: cutting and D:
delivery) (Fig. 1B) (38, 52). Region A, which is the short tail region, is located at the Nterminus and it is the site of biological activity of the toxins. They contain the 63 kDa
glucosyltransferase domain (GTD) that modifies the small GTPases, which regulates
the host cytoskeleton (38, 42). Region B, the long tail region, is located at the Cterminus and consists of combined repeated oligopeptides (CROPs) that form the
receptor binding domain (RBD). The RBD binds to receptors on the host cell and
becomes internalized through receptor-mediated endocytosis. The region C contains
the cysteine protease domain (CPD), which is responsible for autoprocessing of the
glucosyltransferase domain, endocytosis, and translocation of the toxin into the cytosol
of target cells. Also contained in region C of both TcdA and TcdB is a three-helix bundle
region, conserved in both toxins and located at the junction of GTD-CPD region (39, 42,
3

52). The D region contains the delivery hydrophobic domain, which is responsible for
translocation into the cytosol and binding to the GTPase of target cells in the host
(38). Also, part of the D domain is the small globular sub-domain (SGD) and an
elongated hydrophobic helical stretch containing four α-helices (38, 52).
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Figure 9: (A) The schematic representation of the components of the C. difficile
toxin pathogenicity locus (PaLoc) and (B) the multi-modular domain structure of
TcdA and TcdB. The PaLoc comprises of tcdR, tcdB, tcdE, tcdA, and tcdC genes. The
tcdR is a 555 bp, positive regulator that encodes an alternative RNA polymerase sigma
factor that regulates tcdA and tcdB expression. tcdB is 7101 bp and encodes toxin B.
The 501 bp tcdE encodes a putative holing domain/protein, which has been suggested
to be responsible for extracellular release of both toxin A and B (38). The tcdA (8133
bp) encodes toxin A, whereas the 699 bp tcdC encodes a negative regulator of toxin A
and B (38). The ABCD model (A, biological activity; B, binding; C, cutting; D, delivery)
domain structure of the two toxins contains the A and C domains, which corresponds to
the N-terminal glucosyltransferase domain (GTD) in red and cysteine protease domain
(CPD) in cyan, followed by the three-helix domain 3HB in blue (38). The D domain
corresponds to the delivery hydrophobic domain (DD) (in yellow), which contains the
small globular domain (SGD). The B domain (in pink), corresponds to the receptor
binding domain (RBD) (38).
5

The mechanism of action of toxin A and B on the mammalian target cells involves
receptor-mediated endocytosis, which leads to protein translocation out of the
endosome. Translocation and release of the toxins in the host cell triggers autoproteolytic processing and subsequently monoglucosylation of host Rho and Ras
proteins (39, 97, 98). The highly repetitive C-terminal domain of the toxin binds to the
target cell and is internalized through endocytosis (52). The N-terminal translocation
across the membrane is facilitated by the low pH of the endosome. The delivery
domain, which is the central region, has hydrophobic residues that changes its
conformation at low pH leading to membrane insertion and pore formation (39, 41, 52).
The N-terminal glucosyltransferase is translocated through the pore and is released into
the cytosol of the target cell to disrupt the small GTPases, such as Rho and Ras
proteins. The Rho and Ras proteins are important in maintaining the integrity of the
cytoskeleton. Rho monoglucosylation results in its inactivation and loss of ability to
polymerize actin filament leading to deregulation of the actin cytoskeleton and loss of
cell-to-cell contact at the tight junctions due to signal disruption (32, 97). This leads to
the release of cytokines from mast cells resulting in fluid secretion, intestinal
inflammation, and apoptosis (16).
Another putative virulence factor, CDT binary toxin, also contributes to C. difficile
pathogenesis (32). This toxin disrupts the cytoskeleton and forms microtubule-based
projections that facilitate C. difficile adherence to the surface of epithelial cells. About
35% of C. difficile strains secret the binary toxin, which is encoded by cdtA and cdtB
(35). There are two domains: CDTa, the biologically active ADP-ribosyltransferase that
modifies actin and CDTb, the binding component, which is involved in binding and
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transportation of the enzymatic component into the cytosol. ADP-ribosyltransferase
modifies monomeric G-actin and inhibits its polymerization as ADPribosylated actin
attaches to the barbed end of the actin filament. This inhibits elongation and formation
of F-actin leading to cell rounding and death. (34, 36).

Treatment of C. difficile Infections
Antimicrobial agents play an important role in CDI as they are involved in both induction
and resolution (4). Third generation antibiotics cephalosporins and clindamycin were
previously used for treatment of CDI, but they are currently associated with promoting
risk of CDI (4). CDI treatment depends on the disease classification. CDI can be
classified as non-severe to mild, recurrent, severe or complicated, and the type of
treatment depends on the disease severity. Metronidazole is commonly prescribed for
non-severe to mild cases, whereas vancomycin is usually reserved for severe cases
(10). Other antibiotics, such as rifaximin and teicoplanin, are also used (54). Rifaximin is
a non-absorbable oral antibiotic usually prescribed for first and recurrent CDI.
Teicoplanin, a glycopeptide, is similar to vancomycin but is not approved in the United
States (44). Metronidazole is neurotoxic and so is not used for long-term or recurrent
treatment. Vancomycin is usually reserved for severe cases of CDI. Fidaxomicin, a
novel macrocyclic antibiotic, is now being considered as a vancomycin substitute (44,
45).
In addition to treating severe CDI, vancomycin is active against both metronidazoleresistant C. difficile and epidemic strains with high metronidazole tolerance. Second
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and subsequent recurrences of CDI are usually treated with tapered and/or pulsed
doses of vancomycin (10). In severe cases of CDI, vancomycin and metronidazole can
be administered through different routes. Vancomycin is usually given directly into the
colon, though oral and rectal delivery are also recommended. Failure of treatment is
believed to stem from a dynamic ileus (paralysis of the small bowel), which may prevent
the oral vancomycin from reaching the colon and thus be ineffective. Therefore,
vancomycin is injected directly into the colon (75, 76). Combination of intravenous
metronidazole with intracolonic vancomycin administered by nasogastric tube is
recommended by the European Society of Clinical Microbiology and Infectious Diseases
(ESCMID) guideline to be used in severe cases where oral therapy is not effective (3,
46). Vancomycin is recommended by Infectious Disease Society of America for
suspected severe cases. A study that evaluated the appropriateness of CDI empiric
treatment showed that many CDI patients receive inappropriate empirical treatment
without meeting the criteria for severe CDI. Half of this empirical treatment is reportedly
dispensed without confirmation. Therefore, patients are often treated inappropriately
(15).
Metronidazole- and vancomycin-induced collateral damage of the microbiota has
been found to be associated with a high incidence of CDI recurrence following
conventional treatment (14). Although most patients respond well to treatment and have
their standard metronidazole and/or vancomycin antibiotic therapy discontinued after 10
to 14 days, some patients have symptoms that persist or recur after treatment. The rate
of CDI recurrence is between 20 to 35%, and the rate of recurrence increases with each
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subsequent episode (68). One of the identified significant risk factors for relapse is an
initial infection with the BI/NAP1/027 epidemic clone (56).
The recommended treatment following recurrence of CDI is not straight forward,
as metronidazole is not appropriate for prolonged administration (53) and there has also
been a gradual increase of the C. difficile strain with resistance to metronidazole (28,
30). Using the Clinical laboratory standard institute (CLSI) breakpoints, 8% of C. difficile
clinical isolates were found to be resistant to vancomycin in Iran (53) based on a report
of increased resistance and reduced sensitivity to both metronidazole and vancomycin
(54, 55). Treatment failures with these last resort antibiotics is a result of C. difficile
developing resistance to these antimicrobial agents (54).

Antimicrobial Resistance in C. difficile
Antimicrobial resistance is the ability of microorganisms (bacteria, fungi, viruses,
and parasites) to resist the effects of antimicrobial drugs (antibiotics, antifungals,
antivirals, antimalarials, and antihelmintics) (58, 59). Pathogens that are able to resist
multiple antimicrobials are often referred to as “superbugs”. Antibiotic resistance has
become a global threat. In the United States alone, about 2 million people become
infected with bacteria that are resistant to antimicrobials designed to kill them and about
23,000 patients die as a result of antimicrobial-resistant bacteria (27). New forms of
resistance can easily spread across continents with significant speed. The mortality rate
due to antimicrobial resistance is expected to reach about 10 million patients by the
year 2050, with an estimated global cost of $100 trillion (40). The most important cause
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of antimicrobial resistance is the overuse of antibiotics, which is also the leading risk
factor for CDI (4).
C. difficile is resistant to multiple antibiotics (14). Antibiotic resistance is a
significant factor in CDI dissemination among some hospitalized, elderly, and
immunocompromised patients (14). C. difficile is currently resistant to the following
antibiotics previously used for treatment: penicillin, clindamycin, erythromycin,
cephalosporins, fluoroquinolones and tetracycline (27, 28). Clindamycin was identified
as the highest risk factor in 1970, and was replaced by cephalosporin in the 80s, and
most recently fluoroquinolones (6). Studies of antimicrobial resistance of different C.
difficile isolates in North America, Europe, and Asia show that clindamycin resistance
ranges from 15 to 97% (28). The C. difficile strains most reported to be resistant to
different antibiotics in different countries and continents are as follows: (i) 30% of
ribotype 027 strains are resistant to clindamycin, moxifloxacin, and rifampin in North
America; (ii) in the United States, about 98% of ribotype 027 strains are resistant to
moxifloxacin; and (iii) in the Netherlands, ribotype 078, (another hypervirulent strain) is
resistant to ciprofloxacin, erythromycin, imipenem, and moxifloxacin (29, 31).
The hypervirulent BI/NAP1/027, also known as FQ-resistant C. difficile strain, is
characterized by efficient sporulation, high toxin production, and enhanced cytotoxicity
(57). Spore production in C. difficile is an important mechanism of persistence that
facilitates resistance to antibiotics and to the host immune system (28).
Although metronidazole and vancomycin remain the most effective mode of
treatment for most CDI cases, approximately 25% of patients treated with either
antibiotics can recur typically within 4 weeks of completing the primary therapy (15).
10

Currently, C. difficile isolates with increased resistant to metronidazole and vancomycin
are increasing (30).

Metronidazole Mode of Action
Metronidazole (Fig. 2) causes its antimicrobial action by damaging bacterial DNA
through reduction of the nitro group into cytotoxic nitrosoimidazole and nitroradical
anion by thioredoxin reductase (17, 20). The most important system involved in
metronidazole activation is the pyruvate-ferredoxin/ flavodoxin oxidoreductase (PFOR)
system, which works in concert with ferredoxin and glycerol-3-phosphate hydrogenase
to reductively activate metronidazole directly (19). The nitroradical anion reduces O2 to
generate reactive oxygen species, which is highly deleterious to the cell.
Nitrosoimidazole on the other hand, forms an adduct when reacted with non-protein
thiols or proteins. Adduct formation causes both depletion of non-protein thiols and
modification of metronidazole’s target proteins: purine nucleoside phosphorylase (PNP),
thioredoxin, thioredoxin reductase, and superoxide dismutase (SOD) leaving the cell
vulnerable to oxidative stress and eventually death (19, 20).
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Figure 10: Mechanism of action of metronidazole. Under anaerobic conditions,
metronidazole is reduced to nitroradical anion or nitrosoimidazole by thioredoxin
reductase. The nitroradical anion formed reduces O2 and thereby generates reactive
oxygen species causing oxidative damage to the cell. Nitrosoimidazole in the presence
of non-protein thiols forms protein adducts, which modify thioredoxin reductase (TrxR),
thioredoxin (Trx), superoxide dismutase (SOD), metronidazole target protein 1 (Mtp1),
and purine nucleoside phosphorylase (PNP), and eventually causes to cell death (17).
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The Proposed Mechanisms of Metronidazole Resistance in C. difficile.
The exact mechanism of metronidazole resistance has not yet been established in C.
difficile. The nimA-J gene cluster is associated with metronidazole-resistance in
different genera of both Gram-positive and Gram-negative anaerobic bacteria,
including Bacteroides species (80). The nimA-J genes encode an alternative reductase,
which convert nitroimidazoles to a stable and non-cytotoxic amine derivative to
circumvent the toxic species that causes DNA breakage (4, 17, 80). However,
homologs of the nim genes are not present in the C. difficile genome.
Comparative whole genome sequencing analysis of a stable metronidazole-resistant
(RT) 027 strain, a clone resistant to metronidazole and became susceptible upon
freeze-thaw (63) revealed the following mutations: (i) mutations within the sporulation
gene (spo0A) and germination (cspC) loci;(ii) mutations in the ferric uptake regulator
(fur), a putative nitroreductase gene; and (iii) a mutation in the coproporphyrinogen III
oxidase gene (hemN) (60, 61, 62, 4). In another study, a proteomic analysis of a similar
(RT) 027 strain revealed no evidence of association of deficiencies in the PFOR system.
However, an increase in production of the ferric uptake regulator protein (a central
regulator of iron homeostasis in bacteria) was observed in the metronidazole-resistant
(RT) 027 strain (4, 19).
The proposed mechanism of metronidazole resistance is complex (17) (Fig. 3) and
manifests as either a reduced rate of internal concentration of metronidazole due to
increased efflux or by a reduced rate of metronidazole reductive activation by altering
pyruvate fermentation. Other mechanisms that have been suggested to be involved are
reduced iron transport and increased DNA repair efficiency (19), reduced rate of
13

glucose uptake, which alters pyruvate fermentation leading to downregulation of PFOR
and upregulation of lactic acid dehydrogenase (17, 51). During fermentation, PFOR
reduces pyruvate to acetyl-CoA and CO2 releasing electrons. The electrons flow
through PFOR to reduce ferredoxin then proceed to hydrogenase, which is a low redox
carrier (17). It was originally proposed that PFOR in collaboration with ferredoxin were
the only proteins with adequately low redox potential to actively reduce metronidazole in
anaerobic bacteria, but it was later discovered that effectors with high negative midpoint
redox capacities, such as flavodoxin and glycerol-3-phosphate hydrogenase, were
equally able to reductively activate metronidazole directly in C. pasteurianum (17). This
process is inhibited in metronidazole-resistant isolates, as deficiencies in pyruvate
dehydrogenase activity is consistent with changes in the end products of glucose
metabolism (64).

Other proposed mechanisms of resistance include overexpression of efflux pump
genes, which have been shown to be associated with metronidazole resistance in other
bacteria (65). In Bacteriodes species, decrease in metronidazole uptake because of
increased efflux are facilitated by an over active multidrug efflux pump system and this
results in a reduced subsequent reductive activation (19, 65). Also, inactivation of the
recA gene, which is required for generalized DNA repair and recombination, improved
susceptibility of H. pylori to metronidazole and expression of a cloned recA gene from a
metronidazole-resistant strain reportedly increased the level of metronidazole resistance
in E. coli (66). Another mechanism involved in resistance is the mutation of the ferrous
iron transporter FeoAB, which inhibits iron uptake (17, 18).
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Figure 11: Mechanisms of metronidazole resistance. The mechanisms of
metronidazole resistance are complex. Loss of function in various enzymes results in
reduced susceptibility to metronidazole. The enzymes include pyruvate: ferredoxin
oxidoreductase (PFOR), lactate dehydrogenase (LDH), hydrogenase (HYD), DNA
helicase (RecQ), and DNA repair effectors recombinase A (RecA) (18, 19). The
Bacteroides multidrug efflux pump system (BME) also facilitates metronidazole efflux.
Oxygen-insensitive nitroreductase (NfsA) and the nim genes (NIM) reductively
inactivate the nitro group attached to the amino derivative of metronidazole and reduces
it into a stable amino derivative. Crosses (X) indicate reduced activity or uptake
whereas the red arrows indicate the change expression that confers metronidazole
resistance (18).
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Peptidoglycan Biosynthesis and Mechanism of Action of Vancomycin
There are three stages involved in the biosynthesis of cell wall polymers (26)
(Fig. 4). The first stage is the precursor synthesis in the cytoplasm, which involves the
conversion of L-alanine to D-alanine (D-Ala) by the enzyme racemase and then joining
of two molecules of D-Ala by D-alanine-D-alanine ligase (Ddl) to form dipeptide D-AlaD-Ala (26). The second stage involves the formation of the subunit bound to mobile lipid
undecaprenylphosphate. Uracil diphosphate–N-acetylmuramyl-tripeptide is added to the
dipeptide D-Ala-D-Ala to form uracil diphosphate–N-acetylmuramyl-pentapeptide. Uracil
diphosphate–N-acetylmuramyl-pentapeptide is bound to the mobile lipid
undecaprenylphosphate for translocation to the outer surface of the membrane. The
third and the final stage is transglycosylation and transpeptidation, in which Nacetylmuramyl-pentapeptide is attached to the nascent glycan chain by
transglycosylation and finally cross bridge formation by transpeptidation (24, 26).
Vancomycin binds to the C-terminus of D-alanine-D-alanine during cell wall
peptidoglycan biosynthesis to block transglycosylation and transpeptidation reactions
(18, 25). It interferes with the late stage of peptidoglycan assembly. This is evident in
the assembly of cell wall precursor UDP-MurNAc-pentapeptide in the cytoplasm (26).
Vancomycin interaction with the precursor takes place only after translocation to the
outer membrane, since vancomycin cannot penetrate the cell into the cytoplasm.
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Figure 12: Peptidoglycan biosynthesis and mechanism of action of vancomycin.
Vancomycin binds to the C-terminal D-Ala–D-ala of peptidoglycan precursors
preventing the function of transglycosylases, transpeptidases, and the
carboxypeptidases. D-Ala-D-Ala ligase (Ddl) joins the two D-alanines and MurF, the
pentapeptide synthetase flips the precursor (UDP N-acetylmuramyl-pentapetide and Nacetyglucosamine) to get attachment to the growing chain of peptidoglycan precursor
(26).
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Vancomycin Resistance Mechanisms in Gram-Positive Bacteria
The mechanism of acquired vancomycin resistance is well established in
Staphylococcus aureus and Enterococcus spp. However, the mechanism of
vancomycin-resistance in C. difficile is not known. Vancomycin is not target enzymespecific and does not interact with enzymes responsible for cell wall biosynthesis, but
rather is substrate-specific (23, 24). Seven types of vancomycin-resistance associated
genes have been described in Enterococci spp. These are vanA, B, C, D, E, G and L.
Strains that harbor the vanA, B and D genes synthesize D-Ala-D-lactate, instead of DAla-D-Ala, whereas vanC, E, G and L synthesize D-Ala-D-serine. They are all
responsible for creating reduced cell wall affinity to vancomycin and complete
elimination or reduction in the cell wall terminating precursor D-Ala-D-Ala. VanA-type
resistance is the most common and was first to be reported (23). It is characterized by a
high level of resistance to vancomycin and teicoplanin that can also be induced (26).
Vancomycin resistance has also been reported to be regulated by a two-component
system VanSR (67). Changes in the peptidoglycan biosynthetic pathway results in high
level of resistance to vancomycin and other glycopeptides in strains with the vanA
phenotype in both Enterococcus faecium and E. faecalis (69). In a medium containing
glycopeptide, VanS, (Fig. 5) a membrane-associated sensor kinase which contains a
histidine residue in its cytoplasmic domain, is phosphorylated. VanR, a transcriptional
activator containing an aspartate catalyzes the transfer of the phosphoryl group from
activated VanS. Thus, the level of phosphorylation of VanR is controlled by VanS. Cotranscription of the vanH, vanA, vanX, and vanY genes is activated by the
phosphorylated form of VanR by binding to the PRES promoter (74). Phosphorylated
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VanR also activates transcription of the vanR and vanS genes by binding to the PREG
promoter (73).
VanA and VanH synthesize D-Ala-D-lactate (69) and incorporate it into the
peptidoglycan precursors to replace D-Ala-D-Ala (70, 71, 72). A dipeptidase VanX,
hydrolyses D-Ala-D-Ala synthesized by the ligase thereby decreasing the production of
the normal peptidoglycan precursor UDP-MurNAc-L-Ala-D-isoGlu-L-Lys-D-Ala-D-Ala
(UDP-MurNAc-pentapeptide(Ala)) and VanY, , a membrane-bound D, Dcarboxypeptidase enzyme removes the C-terminal D-Ala residues of late peptidoglycan
precursors (67, 73). All of these mechanisms increase resistance to vancomycin.
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Figure 13: Mechanism of vancomycin resistance. Vancomycin prevents
transglycosylation and cross-linking of the peptidoglycan during cell wall synthesis.
Gene clusters that produces peptidoglycan D- Ala-D- Lactate instead of D-Ala-D-Ala
have been found to be associated with VanA resistance. They include the vanH, vanA,
vanX, vanS, vanR, and vanZ gene clusters (21). VanS is a sensor histidine kinase that
senses the presence of vancomycin, VanR is the regulator that activates transcription of
the operon. VanH is a dehydrogenase that produces lactate by converting pyruvate to
D-lactic acid. VanX is a D, D-dipeptidase, which cleaves D-Ala-D-Ala, and VanA is a
ligase that forms D-Ala-D-Lactate. VanY is a carboxypeptidase that cleaves the terminal
D-ala (from pentapeptide to tetrapeptide). The role of VanZ is unknown (99).
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Both in-vivo and in-vitro transfer of the vanA gene from Enterococci species to S.
aureus results in a strain that is resistant to vancomycin. The first MRSA with a very
high resistance to vancomycin (minimum inhibitory concentration >256 μg/ml) was
isolated in 2002 (22).
The past decade has recorded a remarkable increase in CDI treatment failure with both
antibiotics (28). Therefore, a metronidazole-resistant strain was used to explore
potential impact decreased susceptibility may have on the pathophysiology of recurrent
CDI. High level of resistance was once not considered to be responsible (80), however,
recent reports have demonstrated a causal relationship (30).
A preliminary data (not shown) generated from our laboratory showed the present of C.
difficile strains with significantly high-level resistant to metronidazole and vancomycin in
the community. Presently, it is unclear how prevalent metronidazole and vancomycin
resistant C. difficile strains are in healthcare communities. It is important to establish the
prevalence of metronidazole and vancomycin resistance in C. difficile, determine the
minimum inhibitory concentrations (MIC) of the different isolates and identify the
mechanism of resistance in order to be able to design novel targeted therapies.
Therefore, the purpose of this study was to determine the prevalence of metronidazoleand-vancomycin resistance in Clostridium difficile strains isolated from patients and
uncover the resistance mechanism.

21

MATERIALS AND METHODS
Stool Samples
Clinical stool samples were obtained from inpatients, who presented with diarrhea
at St. Luke’s Episcopal Hospital in the Texas Medical Center (TMC), Houston, Texas,
and two hospitals in Kenya: Kenyatta National Hospital, Nairobi, and Kisii Teaching &
Referral Hospital, Kissi. All the obtained clinical stool samples for this study was
approved by the Institutional Review Boards of The University of Texas Health Science
Center at Houston and St. Luke’s Episcopal Hospital (Houston, Texas), and the ethical
review boards of Kenyatta National Hospital and Kisii Teaching and Referral Hospital.
All the stool samples from patients were also de-identified. The samples from St. Luke’s
were tested by their medical laboratory and reported as C. difficile positive, whereas the
Kenyan samples were not tested for C. difficile by their respective microbiology
laboratories. All samples were stored at -80oC until analyzed.
C. difficile Detection
The presence of C. difficile in the stools was determined using the C. difficile Plate
Assay (CDPA). This method utilized an agar-based selective culture medium developed
in our laboratory for differential analysis of C. difficile isolates (11). The assay
differentiates toxin producing C. difficile from non–toxin producing colonies and
concurrently inhibits growth of non- C. difficile colonies (11). CDPA is composed of brain
heart infusion (BHI) medium (Becton Dickinson, Cockeysville, MD) (37 g), agar (14 g),
defibrinated horse blood (7%) (Fisher Scientific, Pittsburgh, PA), 150 mg/ml 5-bromo-4chloro-3-indolyl-β-D-galactopyranoside (Zymo Research Irvine, CA), p-cresol (0.025%),
D-cycloserine (300 mg) and cefoxitin (8.5 mg) (Fisher Scientific), per liter.
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A total of 572 stool samples were tested, of which 466 were obtained from St
Luke’s Episcopal Hospital, 106 were from Kenyatta National Hospital, and Kisii
Teaching and Referral Hospital. A loopful of each stool sample was spread on the
CDPA plate and incubated anaerobically in an atmosphere of 10% H2, 5% CO2, and
85% N2 in a Controlled Atmosphere Anaerobic Chamber (Plas Labs, Lansing, MI) for 48
hours to facilitate both colony formation and toxin production. To enable the
chromogenic reaction, which differentiates toxin from non-toxin producing C. difficile, the
plates were exposed to oxygen at room temperature after the anaerobic incubation.
Toxin producing colonies appeared blue while undetectable or non-toxin producing
colonies appear pale white.
Screening for Resistant Isolates
CDPA plates containing 8 µg/ml of metronidazole (CDPA-Metro) and CDPA plates
containing 4 µg/ml of vancomycin (CDPA-Van) were used in screening for
metronidazole and vancomycin resistant isolates, respectively. The initial concentrations
of vancomycin and metronidazole used were based on the CLSI break point (30). Using
a sterilized loop, each C. difficile-positive stool sample was spread directly onto the
CDPA-Metro and CDPA-Van plates and were incubated anaerobically at 37oC for 48
hours. All stool samples were grouped into metronidazole-resistant only (Met-R only),
these are stool samples that formed viable colonies on CDPA-Metro plates only,
vancomycin-resistant only (Van -R only), these are stool samples that formed viable
colonies on CDPA-Van plates only and both metronidazole and vancomycin resistant
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(Met-Van-R) are stool samples that grew viable colonies on both CDPA-Metro and
CDPA-Van plates (Fig. 6).

Figure 14: Screening steps for isolating metronidazole- and vancomycin-resistant
C. difficile colonies from stool samples. This chart details steps employed to screen
the 466 stool samples from Texas and 102 stool samples from Kenya. CDPA plates
were used to determine C. difficile positive stool samples, whereas CDPA +
Metronidazole (8 μg/ml) and CDPA + Vancomycin (4 μg/ml) were used to screen for
metronidazole- and vancomycin-resistant positive stool samples.
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DNA Isolation
Frozen isolates (stock of resistant isolates) were cultured in 5 ml BHI media
supplemented with D-cycloserine (250 µg/ml) and cefoxitin (8.5 µg/ml), and were
incubated anaerobically at 37oC overnight. DNA was isolated using Gen Elute Bacteria
Genomic DNA Kit (Sigma-Aldrich, St. Louis, MO), following the manufacturer’s
recommended procedure. The concentration of the isolated DNA was measured using a
NanoDrop 2000 Spectrophotometer (Thermos Scientific, Waltham, MA). All DNA was
stored at -20oC until analyzed.
Toxin Analysis
The C. difficile toxin activity (Cdifftox) assay was used to measure toxin activity in the
resistant isolates. The Cdifftox assay employs the ability of the C. difficile toxins to
cleave p-nitrophenyl-β-D-glucopyranoside into chromogenic nitrophenol, which can be
measured spectrophotometrically at 410 nm (11). For the toxin test, 20 different
resistant isolates with different MICs were cultured in BHI broth containing Dcycloserine (250 µg/ml) and cefoxitin (8.5 µg/ml) and incubated at 37oC in anaerobic
chamber (PLAS LABS, Lansing, MI) for 48 hours and the cells were harvested by
centrifuging at 4000 rpm for 15 minutes. The culture supernatants (250 µl) were added
into a sterile Costar polystyrene 96-well plate and 30 µl of substrate (sterilized 30 mM of
p-nitrophenyl-β-D-glucopyranoside in water) was added and incubated aerobically at
37oC for 4- 24 hours. The cleaved substrate was measured at 410 nm wavelength using
SPECTRAmax Plus 384 spectrophotometers (Molecular Devices, Sunnyvale, CA).
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Determination of Minimum Inhibitory Concentrations
The minimum inhibitory concentrations (MIC) of metronidazole and vancomycin were
determined using two methods. These are the E-test Strip method (also called the
(Epsilometer test) method (60), and the broth microdilution methods (60).
(i) E-test Strip Method
E-test strip (Biomerieux inc, Durham, NC) is a gradient diffusion assay
recommended by CLSI for determining antimicrobial susceptibility profile in both clinical
and epidemiological surveillance (60). To assess the level of resistance, 53 resistant
isolates from Texas were randomly selected (Table 1) and MICs for metronidazole and
vancomycin were determined using the E-Strip method. The MIC range on the stripe
was from 0.16 μg/ml to 256 μg/ml for both metronidazole and vancomycin. For the test,
single colonies were picked from a CDPA plate and suspended in 1000 μl of sterile 1X
phosphate buffered saline (PBS). A sterilized cotton swab was used to spread the
culture onto a BHI agar plate containing 7% horse blood. Two different strips
impregnated with gradient concentrations (0.16-256 µg/ml) of metronidazole or
vancomycin were placed onto each plate using sterilized forceps and incubated
anaerobically at 37o for 24 hours. The MICs were determined based on the zone of
inhibition.
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Table 1: Different number of Isolates and their corresponding resistance group.
The minimum inhibitory concentration of metronidazole and vancomycin was
determined on colonies selected from the metronidazole-resistant only (Met-R only),
vancomycin-resistant only (Vanc-R only) and both metronidazole and vancomycin
resistant (Met-Van-R) isolates. Overnight cultures of single colonies of each isolate
were spread on BHI plates containing blood using a sterilized cotton swab. E-test strips
containing graduated concentration of metronidazole and vancomycin (0.5 - 256µg/ml)
were separately placed onto the plate and incubated anaerobically overnight at 37°C to
determine their various MICs.

Category

Number of Isolates

Met-R Only

15

Van-R Only

4

Met-Van-R

34
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(ii) MIC Determination by the Broth Microdilution Method
Overnight cultures prepared from stored resistant colonies selected from CDPA
plates were used. For the test, 4 µl of overnight cultures of each isolate was added in
duplicate to a sterile Costar polystyrene 96-well plate (Corning Inc., NY) containing 200
µl of BHI supplemented with D-cycloserine (250 µg/ml), cefoxitin (8.5 µg/ml), gradient
concentrations of metronidazole or vancomycin (2-1024 µg/ml) separately and
incubated anaerobically at 37oC for 24 hours. The optical densities of the culture were
measured at a wavelength of 600 nm.
PCR Amplification of the vanA gene in the isolates
PCR was used to examine the presence of the vanA gene in the vancomycinresistant C. difficile stored isolates. The amplification was performed using the primers:
Forward 5’GGGAAAACGACAATTGC3’ and Reverse 5’GTACAATGCGGCCGTTA3’.
The conditions used were: denaturation at 94oC for 2 min, 40 cycles of 94oC for 30
secs, 55oC for 60 seconds, and 68oC for 90 seconds and a final elongation step at 68oC
for 5 min. The PCR products were analyzed using 1% agarose gel electrophoresis and
ethidium bromide staining.
Ligation and Cloning
Following amplification, the PCR products were purified with the Nucleic Acid
Purification Kit (Epoch Life Science) following manufacturer directions. The DNA
concentration was quantified using a Nanodrop 2000 Spectrophotometer. The purified
PCR products were cloned into PCR II vector (Thermo Scientific) and sequenced at
Lone Star Labs, Houston, Texas. For cloning and ligation, the manufacturer’s protocol
was followed. Briefly, 10 μl of ligation reaction was set up using 50-200 ng DNA, 2 μl of
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5X ExpressLink T4 DNA Ligase Buffer, 2 μl PCR II vector (25 ng/μl), 3μl of water, and
1μl of ExpressLink T4 DNA Ligase. The ligation reaction was incubated at room
temperature for 15 minutes and used for transformation as described below.
Transformation
Top10 competent cells were thawed on ice and 100 μl of the thawed competent cells
was added into a microfuge tube on ice, 2 μl of each ligation reaction was added
separately in each tube containing the competent cells. The content of each tube was
gently mixed with a pipette, incubated on ice for 30 minutes, and 100 μl of the
transformation reaction was spread on Luria Broth (LB) agar plates containing 100
μg/ml of ampicillin and 150 μg/ml of X-gal. The plates were incubated at 37 oC
overnight. The transformants (3 colonies each) were picked from each plate and
cultured in LB broth containing 100 μg/ml ampicillin and incubated at 37 o C in a MaxQ
4000 shaker (Thermo Scientific) at 275 rpm overnight. Stocks were saved, and
plasmids were isolated using Plasmid Isolation Kit (BioBasic Inc), as directed by the
manufacturer. The concentration of each isolated plasmid was quantified using a
Nanodrop 2000 Spectrophotometer and the plasmids were sent for sequencing at
LoneStar Labs (Houston, Texas).
Sequence Analysis
The transformants containing the inserts with the plasmids were isolated and
sequenced. The plasmid was identified and removed from the sequence. Both the
forward and reverse sequences were merged using MAFFT and multiple sequence
alignment was performed using CLUSTALW.
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Biofilm Formation Analysis
To evaluate the rate of adhesiveness or the amount of biofilm produced by the
vancomycin-resistant isolates when exposed to vancomycin, three resistant isolates 624, 255-1, and 67-2 were tested. The vancomycin MICs of these isolates determined by
the broth microdilution method are (i) low resistance, MIC 4 µg/ml (isolate 62-4); (ii)
intermediate resistance, MIC 64 µg/ml (isolate 255-1); and (iii) high resistance, MIC
1024 µg/ml (67-2).
Overnight cultures of the isolates were prepared in BHI supplemented with Dcycloserine (250 µg/ml) and cefoxitin (8.5 µg/ml) and incubated anaerobically at 37oC.
BHI medium supplemented with 1% glucose was prepared for the control, while BHI
supplemented with 1% glucose and vancomycin at concentrations corresponding to ½
and ¼ of the MICs of the isolates was prepared for the experimental as follows:
(1) Low resistance, MIC 4 µg/ml (62-4): BHI supplemented with 1% glucose
containing 2 µg/ml or 1 µg/ml vancomycin.
(2) Intermediate resistance, MIC 64 µg/ml (isolate 255-1): BHI supplemented with
1% glucose containing 32 µg/ml or 16 µg/ml of vancomycin.
(3) High resistance, MIC 1024 µg/ml (67-2): BHI supplemented with 1% glucose
containing 512 µg/ml or 256 µg/ml vancomycin.
For the control without vancomycin, 200 µl of overnight culture of each of the isolates
were added in triplicate into 24-well polystyrene plates containing 1800 µl of BHI
supplemented with 1% glucose. For the experimental group, 200 µl of the culture were
added in triplicate into 24-well polystyrene plates and 1800 µl of BHI supplemented with
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1% glucose containing different concentrations of vancomycin, as described above. All
the samples were incubated at 370C anaerobically for 72 hours.
Following the incubation period, the amount of biofilm produced was measured (59).
Briefly, the supernatant of all the wells was gently removed and each well was washed
twice with 2000 µl of sterilized 1X PBS. The plates were dried at 60 oC for 1 hour. The
dried wells were stained with 150 µl of 2% crystal violet and incubated at 37oC for 15
minutes. The excess stain was washed out with deionized water and the plates were
dried at 60oC for 10 minutes. The crystal violet bound to the adherent cells was
extracted with 1800 µl of 100% ethanol. The optical density was measured at 570 nm
wavelength using SPECTRAmax Plus 384 spectrophotometers. The experiment and
the assay were performed three times.
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RESULTS
To determine the prevalence of metronidazole-and-vancomycin resistance in C. difficile,
all the C. difficile positive stool samples and stool samples containing metronidazoleresistant and vancomycin-resistant C. difficile were enumerated and classified as
follows. Stool samples that contains C. difficile that grew on CDPA plates were
classified as C. difficile positive stool samples whereas, those that did not grow were
classified as C. difficile negative stool samples. All stool samples that contain C. difficile
strains that grew on plates containing metronidazole only were grouped as
metronidazole only resistant stool sample (Met-R), all stool samples that contain C.
difficile strains that grew on plates containing vancomycin only were grouped as
vancomycin only resistant stool sample (Van-R) and all stool samples that contain C.
difficile strains that grew on both metronidazole and vancomycin plates were grouped
as metronidazole-vancomycin resistant stool sample (Met-Van-R).
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Table 2: Distribution of the number of patients having metronidazole- and
vancomycin-resistant C. difficile strains in their stool. The samples were
grouped as described, Met-R, Van-R and Met-Van-R. The total number and percent
relative to the C. difficile positive samples, metronidazole- and vancomycin- resistant from
both Texas and Kenya patients is shown.

C. difficile positive stools

Met-R Only

Texas

Kenya

N (%)

N (%)

438 (93.9)

31 (7)

98 (96)

26 (26.5)

Vanc-R Only

17 (3.9)

9 (9.1)

Met-Van-R

97 (22.1)

57 (58.2)

Total Met-R

128 (29.2)

83 (84.7)

Total Van-R

114 (26)

66 (67.3)

145 (33.1)

92 (93.9)

Total (Met-R + Van-R
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Distribution of Metronidazole- and Vancomycin-Resistant C. difficile in CDI
Patients
To determine the percent of C. difficile positive stool samples, metronidazole and
vancomycin resistant stool in samples from Texas and Kenya, the number of C. difficile
positive and negative stool samples were enumerated and grouped (Table 2) as
metronidazole resistant stool samples (Met-R only), vancomycin-resistant only (Van-R
only) samples, and both metronidazole and vancomycin resistant stool samples (MetVan-R).
To establish the prevalence of metronidazole- and vancomycin-resistant C. difficile,
CDI-positive stool samples were plated on CDPA plates containing either metronidazole
or vancomycin at their reported CLSI cutoff values (8 µg/ml and 4 µg/ml respectively).
All stool samples that grew viable colonies only on the metronidazole-containing plates
were grouped as (Met-R only), stools that grew viable colonies only on the vancomycincontaining plates (Van-R only) and stools samples that grew colonies on both
metronidazole and vancomycin plates (Met-Van-R). From Texas stool samples 438
(93.9%) contained colonies that were C. difficile positive, 31 (7%) were Met-S only, 17
(3.9%) were Vanc-R only and 97 (22.1%) were Met-Van-R. From the Kenya stool
samples, 98 (96%) were C. difficile positive, 26 (26.5%) were Met-R only, 9 (9.1%) were
Vanc-R only and 57 (58.2%) were Met-Van-R. (Table 2). Overall, the total numbers of
resistant stool samples were Met-R, 128 (29.2%), Van-R, 114 (26%) and Met-Van-R
145 (33.1%).
For further analysis, five different colonies were selected from each plate containing
resistant stool samples from Texas and at least two from the Kenyan stools. All the
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colonies were picked and cultured anaerobically overnight in BHI broth containing Dcycloserine (250 µg/ml), cefoxitin (8.5 µg/ml) and their respective antibiotics (8 μg/ml of
metronidazole or 4 μg/ml of vancomycin). The number of viable colonies that represent
the number of stored independent isolates from all the metronidazole and vancomycin
resistant stool samples was recorded (Fig. 7).

Figure 15: Isolation of metronidazole- and vancomycin-resistant C. difficile
colonies from the stools. CDI stools were plated on CDPA plates containing either
metronidazole (8µg/ml) or vancomycin (4 µg/ml). Following a 24-hour incubation,
colonies (5 from Texas and at least 2 from Kenya stools) were selected for further
analysis.
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Characteristics of the Colonies Based on Morphology and Toxin Production
Of the C. difficile positive stool samples from Texas and Kenya, 157 (35.9%) and 5
(5.1%), respectively, of the samples produced only blue colonies on the CDPA plates,
indicative of active toxin production. On the other hand, the plates for 122 (27.9%) of the
Texas samples and 9 (9.2%) of the Kenya samples produced had only white colonies
(Table 3). This suggests that the colonies were not producing active toxins or cannot
produce active toxins. The colonies from 159 (36.3%) of Texas and 84 (85.7%) of the
Kenyan patients had mixed blue and white (both toxin and non-toxin) colonies on the
plates.
The sizes of the colonies in each plate were also analyzed and classified as (a) small,
(b) medium, (c) large, and (d) a mixture. The classification is the different sizes
observed and therefore, subjective. Of the stool samples analyzed, 245 of the patients
from Texas and 45 patients from Kenya had C. difficile isolates that formed only small
colonies. Further, 49 of the Texas and 3 of the Kenyan samples formed medium sized
colonies only, whereas 18 of the Texas and 6 of the Kenyan samples formed large
colonies only. Also, 58 of the Texas and 20 of the Kenyan samples formed a mixture of
small and medium colonies, while 10 (Texas) and 1 (Kenya) samples formed a mixture
of medium and large colonies. Finally, 42 of the Texas and 19 of the Kenyan samples
formed a mixture of small and large colonies whereas 16 (Texas) and 4 (Kenyan)
samples formed a mixture of small, medium and large colonies. These results indicated
that many Texas and most Kenyan CDI patients are infected with C. difficile strains that
are morphologically different.
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Table 3: The characteristics of the C. difficile colonies isolated from patients from
Texas and Kenya.
Morphology

Texas

Kenya

Number of

Number of

Samples

Samples

Small colonies only

245

45

Medium colonies only

49

3

Large colonies only

18

6

Mixture of small and

58

20

10

1

42

19

16

4

Total

438

98

Blue colonies only

157

5

While colonies only

122

9

Mixture of white and blue

159

84

medium colonies
Mixture of medium and
large colonies
Mixture of large and
small colonies
Mixture of small, medium
and large

colonies
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The Minimum Inhibitory concentrations (MIC) of the C. difficile strains
To determine the MICs of the isolates from metronidazole- and vancomycin-resistant
stools, the E-test strip assay was used to test 53 randomly selected isolates from
Texas. The result revealed that the metronidazole MIC of 52 (98.1%) of the isolates was
greater than 256 µg/ml, and only 1 (1.9%) was sensitive with an MIC 1.0 µg/ml (Table
4). Also, the vancomycin MIC of 35 of the isolates (77.4%) was greater than 256 µg/ml,
5 had MICs between 8-16 µg/ml, whereas 12 (22.6%) had MICs less than 4 µg/ml.
Since the majority of the 53 samples initially tested by the E-test strip method have
MICs greater than 256 µg/ml, the broth microdilution method was used to determine the
exact MICs of all the resistant isolates. This is because this method does not have a
limitation on the antibiotic concentration to be tested, contrary to the E-test strip method
whose maximum concentration is 256 µg/ml for both metronidazole and vancomycin.

Out of 145 resistant isolates from Texas, three isolates did not grow in the liquid, so 142
were tested for their MIC using broth microdilution method. From this analysis, 80%
(114 out of 142 resistant isolates) from Texas colonies were vancomycin resistant with
MIC >16 µg/ml whereas 41% (38 out of 92 resistant isolates) from Kenya were
vancomycin resistant with MIC >16 µg/ml. 97.8% (139 out of 142 resistant isolates) from
Texas population were metronidazole resistant with MICs ˃ 256 µg/ml whereas 97% (90
out of 92 resistant isolates) from Kenya were metronidazole resistant with MICs > 256
µg/ml.
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Table 4: The MIC of 53 C. difficile isolates using E-test strip method. The MIC
breakpoint was based on guideline recommended for anaerobes by Clinical and
Laboratory Standard Institute (CLSI), which is 8 µg/ml for metronidazole and 4 µg/ml for
vancomycin.
Number of Isolates
Concentration

Metronidazole

Vancomycin

0.5

-

1

1

1

-

2

-

8

3

-

3

4

-

-

8

-

2

12

-

2

16

-

2

>256

52

35

(μg/ml)
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Pearson’s test of association between resistance and location showed a high tendency
of C. difficile isolates to be metronidazole resistant in Kenya than Texas (p-value ≤
0.001). This might be as a result of frequent self-medication with metronidazole.
Unexpectedly, the tendency to develop vancomycin resistant is equally higher in Kenya
than Texas (p-value ≤ 0.001), even with no history of vancomycin treatment. Both
metronidazole- and- vancomycin resistance were prevalent in Kenya than Texas.

40

Table 5: The MICs of the metronidazole and vancomycin-resistance C.
difficile isolates determined using the broth microdilution method.
Metronidazole
Concentration

Vancomycin

Texas

Kenya

Texas

Kenya

(n= 142)

(n= 92)

(n= 142)

(n= 92)

2

3

2

11

42

4

-

-

10

3

8

-

-

4

2

16

-

1

3

7

32

-

-

1

5

64

4

1

4

2

128

3

-

1

5

256

2

4

9

7

512

7

8

23

4

>1024

123

76

76

15

(µg/ml)
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Table 6: Distribution of the isolates based on both CLSI and European Committee
on Antimicrobial Susceptibility Testing (EUCAST) guidelines. CLSI and EUCAST
Cut off values are as follows: EUCAST: Susceptible is ≤2mg/L, Resistant is ˃2mg/L and
the Cut off is ≤2mg/L, for both metronidazole and vancomycin. CLSI: ≤8/16/ ≥32
(Sensitive/Intermediate/Resistant) for metronidazole and ≥4µg/ml for vancomycin.
Texas (n = 142)

Metronidazole

Kenya (n = 92)

CLSI

EUCAST

CLSI

EUCAST

11

11

42

42

3

3

2

2

128

128

48

48

resistant only
Vancomycin
resistant only
Both
Metronidazole
and
Vancomycin
resistant
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Cluster Analysis of the MICs
Cluster analysis reveals that a significant number of the isolates (123/145 for the
Texas isolates and 76/91 for the Kenya isolates) had MIC >1024 µg/ml for
metronidazole. There was a wide gap in MIC range among the metronidazole isolates
in both patient populations with 139 (97.9%) having MIC >64 µg/ml (for the Texas
samples) and 89 (96.7%) for Kenyan samples (Fig. 8). The MICs for the vancomycinresistant isolates were spread across different concentrations in both patient
populations. However, a higher number of the isolates 99 (68.3%) had vancomycin MIC
of ≥512 µg/ml for the Texas samples. Remarkably, isolates with resistance to high
levels of metronidazole was predominant in both Texas and Kenyan patients. Based on
the distribution of the MICs, the resistant isolates can be grouped into three categories:
(i) Low resistance (4-16 µg/ml); (ii) intermediate resistance (32-64 µg/ml); and (iii) high
resistance (64 - ˃1024 µg/ml).
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Metronidazole
CLSI cutoff= 8 µg/mL

1250

1000

( g /m l)

M in im u m in h ib it o r y c o n c e n t r a t io n

1500

750

500

250

0
T exas

Vancomycin
CLSI cutoff= 4 µg/mL

1250

1000

( g /m l)

M in im u m in h ib it o r y c o n c e n t r a t io n

1500

Kenya

750

500

250

0
T exas

Kenya

Figure 16: Distribution of metronidazole- and vancomycin-resistant Texas and
Kenyan C. difficile isolates based on MICs. The red line is the median and the solid
line represents number of highly resistant isolate with MIC of 1024 µg/ml. Each dot
represents a colony.
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Analysis of Toxin Production in Both Texas and Kenya Resistant Isolates
Twenty isolates with different levels of resistance (Fig. 9) from Texas and Kenya were
selected to explore the association between toxin production and antibiotic resistance.
The isolates were grown in BHI containing D-cycloserine (250 µg/ml) and cefoxitin (8.5
µg/ml) anaerobically at 37oC for 48 hours. The culture supernatants were tested for
toxin activity by mixing 250 µl of the supernatant with 30 µl of the substrate. Sixteen out
of twenty isolates from Texas were toxin positive (Tox+) whereas 15 out of the twenty 20
isolates from Kenya were Tox+.
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Figure 17. Analysis of toxin production by the metronidazole and vancomycin
resistant isolates. Both toxin-producing (Tox+) and non-toxin-producing (Tox-) isolates
are represented from different groups of resistant isolates: low resistance (4-16 μg/ml),
intermediate resistance (32-64 μg/ml) and high resistance (32-64 μg/ml). Stored isolates
(20) were cultured for 48 hours and 250 µl of each culture supernatant was incubated
with toxin substrate (30 mM p-nitrophenyl-β-D-glucopyranoside) for 4 hours. The toxin
present in culture supernatant cleaves the chromogenic toxin substrate and generates
yellow colored nitrophenol whose absorbance is read at 410nm in a spectrophotometer.
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Analysis of Biofilm Formation of the Resistant Isolates
Biofilm has been suggested to be associated with vancomycin resistance (30). To
investigate the effect of vancomycin on the ability of the resistant isolates to form
biofilms, isolates with different MICs were evaluated. This experiment was based on the
hypothesis that if the low- and intermediate-resistant isolates, but not highly-resistant
isolates, use biofilm as a defensive mechanism when exposed to vancomycin, then the
degree of biofilm formation in those isolates should increase. To test this hypothesis,
the isolates were exposed to sub-inhibitory concentrations of vancomycin for 72 hours
and biofilm production was measured. There was no significant difference (p=0.3554)
in the amount of biofilm produced in the presence or absence of vancomycin in all the
isolates tested (Fig. 10).
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Figure 10: Effect of vancomycin on biofilm formation on vancomycin-resistant C.
difficile isolates. Cultures with different vancomycin MICs were exposed to different
amounts of vancomycin for 72 hours and biofilm produced was measured. The blue,
purple, and green bars represent the low, intermediate and high resistant isolates
respectively. The different isolates were grown without vancomycin, or in the presence
of vancomycin at concentrations equivalent to ¼ MIC or ½ MIC values of the isolates.
Error bars represent the standard deviation from three independent replicates.
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PCR- Based Detection of the vanA Gene in the Vancomycin Resistant Isolates.
To evaluate the presence of vanA gene in the resistant isolates, PCR was
performed using a primer pair specific for vanA in Enterococcus faecium. A total of 40
vancomycin resistant isolates were tested and all were positive for the vanA gene (Fig.
11).

Figure 11: A representative agarose gel electrophoresis images showing the
expected vanA bands in the C. difficile isolates tested. Genomic DNA was isolated
from the resistant isolates and used as templates for PCR with primers specific for the
vanA gene in E. faecium. The PCR product was resolved on 1% agarose and stained
with ethidium bromide. M is 1kb DNA marker, lanes 1 and 14 are the vanA amplicons
and –VE is the negative control with no DNA.
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Sequence Comparison of Putative C. difficile vanA gene with the Enterococcus
Faecium Homolog
To confirm the presence of the C. difficile vanA gene and also enable comparison
to the E. faecium homolog, the vanA PCR products were purified and sequenced. The
sequence alignment is shown (Fig. 12). When C. difficile vanA sequence is compared to
vanA of E. faecium there is a significant measure of divergence in the 5’ end compared
to 3’ end which is more conserved.

Enterococcus faecium
394-3L-VANA
382-3BA-VANA
382-3AA-VANA
244-4A-VANA
237-2-VANA
231-4A-VANA
212-5A-VANA
134-2L-VANA
382-3AA1-VANA1
244-4A1-VANA1
212-5A1-VANA1

90
100
110
120
130
140
150
160
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
AAAA-TCTGCAATAGAGATAGCCGCTAACATTAATAAAGAAAAATACGAGCCGTTATACATTGGAATTACGAAATCTGGT
-------------------------------------------------------------------------------AAAAATCTGCAATAGAGATAGCCGCTAACATTAATAAAGAAAAATACGAGCCGTTATACATTGGAATTACGAAATCTGGT
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------AAAA-TCTGCAATAGAGATAGCCGCTAACATTAATAAAGAAAAATACGAGCCGTTATACATTGGAATTACGAAATCTGGT
--------------------------------------------------------------------------------------------------------------------------------------------------------------AAA--TCTGCAATAGAGATAGCCGCTAACATTAATAAAGAAAAATACGAGCCGTTATACATTGGAATTACGAAATCTGGT
AAAA-TCTGCAATAGAGATAGCCGCTAACATTAATAAAGAAAAATACGAGCCGTTATACATTGGAATTACGAAATCTGGT
AAAA-TCTGCAATAGAGATAGCCGCTAACATTAATAAAGAAAAATACGAGCCGTTATACATTGGAATTACGAAATCTGGT

Enterococcus faecium
394-3L-VANA
382-3BA-VANA
382-3AA-VANA
244-4A-VANA
237-2-VANA
231-4A-VANA
212-5A-VANA
134-2L-VANA
382-3AA1-VANA1
244-4A1-VANA1
212-5A1-VANA1

170
180
190
200
210
220
230
240
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
GTATGGAAAA-TGTGCGAAAAACCTTGCGCGGAATGGGAAAACGACA-ATTGCTATTCAGC-TGTACTCTCGCC-GGATA
---------------------------------------------------------------GCACGTCGGTC-----GTATGGAAAAATGTGCGAAAAACCTTGCGCGGAATGGGAAAACGACA-ATTGCTATTCAGC-TGTACTCTCGCC-GGATA
------------------------------TTGGGGAAAAAACGG---ATTGCTATTCATTGTGTACTCTCGCC-GGATA
-------------------------------GATTGGGAAAAAAAGGAATTGCTTTTCAGC-TGTACTCTCGCC-GGATA
---------------------------------------------------------------GCAAGTCGGTG-----GTATGGAAAA-TGTGCGAAAAACCTTGCGCGGAATGGGAAAACGACA-ATTGCTATTCAGC-TGTACTCTCGCC-GGATA
---------------------------------TGGGAAAAAAAACGCATTGCTATTCAGC-TGTACTCTCGCC-GGATA
---------------------CCCTTCCCTTTGGGGGTAAAACGACAAATTGTTATTCAGC-TGTACTCTCCCCCGGATA
GTATGGAAAA-TGTGCGAAAAACCTTGCGCGGAATGGGAAAACGAC-AATTGCTATTCAGC-TGTACTCTCGCC-GGATA
GTATGGAAAA-TGTGCGAAAAACCTTGCGCGGAATGGGAAAACGAC-AATTGCTATTCAGC-TGTACTCTCGCC-GGATA
GTATGGAAAA-TGTGCGAAAAACCTTGCGCGGAATGGGAAAACGAC-AATTGCTATTCAGC-TGTACTCTCGCC-GGATA

Enterococcus faecium
394-3L-VANA
382-3BA-VANA
382-3AA-VANA
244-4A-VANA
237-2-VANA
231-4A-VANA
212-5A-VANA
134-2L-VANA
382-3AA1-VANA1
244-4A1-VANA1
212-5A1-VANA1

250
260
270
280
290
300
310
320
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
AAAAAATGCACGG-ATTACTTGTTAAAAAGAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCA
-----GTGCACGG-ATTACTTGTTAAAAAGAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGTA
AAAAAATGCACGG-AT-ACTTGTTAAAA-GAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCA
AAAAAATGCACGG-AT-ACTTGTTAAAA-GAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCA
AAAAAATGCACGG-AT-ACTTGTTAAAA-GAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCA
----GATGCACGGCATTACTTGTTAGAA-GAACCATGA-TATCGACTCAACCATGTTGATGTAGCATTTTCAGCTTTG-A
AAAAAATGCACGG-AT-ACTTGTTAAAA-GAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCA
AAAAAATGCACGG-AT-ACTTGTTAAAA-GAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCA
AAAAAATGCACGG-AT-ACTTGTTAAAA-GA-CCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCA
AAAAAATGCACGG-ATTACTTGTTAAAAAGAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCA
AAAAAATGCACGG-ATTACTTGTTAAAAAGAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCA
AAAAAATGCACGG-ATTACTTGTTAAAAAGAACCATGAATATGAAATCAACCATGTTGATGTAGCATTTTCAGCTTTGCA

Figure 12: Sequence alignment from the PCR product of the amplified segment
of the C. difficile vanA gene. The alignment appears to be divergent at the 5’ region
and more conserved in the 3’.
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VanA Amino Acid Sequence Alignment
The DNA sequences obtained from the isolates were translated into amino acid and
aligned to the vanA amino acid sequence from Enterococcus faecalis (Fig. 13). Cluster
analysis was performed to determine the percentage of similarity and most of the
sequences were 97.27-100% similar. It appears the differences in the sequence did not
impact the antibiotic resistance activity as the isolate with the lowest similarity in the
sequence has a high degree of vancomycin resistance of 512 μg/ml compared to as the
others. However, due to the low quality of the sequences obtained at the 5’ and 3’ ends,
we were not able to obtain the full-length version of the C. difficile vanA from the
isolates. This will be addressed in a planned future study.
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E-faecalis_VanA
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--------------------------------------------------XENDNCYSAVLSPDKKMHGLLVKKNHEYEI
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--------------------------------------------------XENDNCYSAVLSPDKKMHGLLVKKNHEYEI
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100
110
120
130
140
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160
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV
NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV
NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV
NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV
NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIHSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV
NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV
NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV
NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV
NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPA
NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV
NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV
NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATLTYPV
NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV
NHVDVAFSALHGKSGEDGSIQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGIATPAFWVINKDDRPVAATFTYPV
NHVDVAFSALHGKSGEDGSMQGLFELSGIPFVGCDIQSSAICMDKSLTYIVAKNAGITTPAFGVINKEDRPGAVTLTYPV
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FVKPARSGSSFGVKKVNSADELDYAIESARQYDSKILIEQAVSGCEVGCAVLGNSAALAVGEVDQIRLQYGIFRIHQEVE
FVKPARSGSSFGVKKVNSADELDYAIESARQYDSKILIEQAVSGCEVGCAVLGNSAALAVGEVDQIRLQYGIFRIHQEVE
LVNPERSGSSFGVKKVNTADK*NYAIESARQYDSKILID*VVSGCEVGGAVLGNRAALAVGEVDQIRLQYGIFRINQEVE
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Figure 13: VanA amino acid sequence alignment of the resistant isolates.
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DISCUSSION
Clostridium difficile infections are the most common hospital acquired infection and
currently treated with metronidazole and vancomycin (4). The unexpectedly high
percent of C. difficile metronidazole and vancomycin resistant isolates from a
preliminary study in our laboratory was of great concern and led to the hypothesis that
metronidazole and vancomycin resistant C. difficile is more widespread in the patient
population that previously envisaged. The objective of this study was to determine the
prevalence of metronidazole- and- vancomycin resistance in C. difficile strains and
uncover the resistance mechanism.
The result of the initial analysis of the metronidazole and vancomycin resistant C.
difficile strains in stools of diarrhea patients from Texas and Kenya demonstrated that
metronidazole and vancomycin resistance is prevalent in CDI patients. Our analysis to
determine the level of metronidazole and vancomycin resistance of each isolate from
the stool sample revealed a high degree of resistance to either or both antibiotics. The
two methods of MIC determination (E-test strip and broth microdilution assays) showed
C. difficile isolates with high MICs to both antibiotics and for the first time C. difficile
isolate with vancomycin MIC >1024 µg/ml was isolated. Cluster and statistical analysis
revealed that the percentage of metronidazole resistant isolates was greater than
vancomycin resistant isolates in both patient populations examined, and there is a
greater tendency for a C. difficile isolate to be metronidazole – or – vancomycin
resistant in Kenya than Texas. PCR analysis of the vancomycin-resistant isolates
revealed the presence of a vanA, gene responsible for vancomycin resistance in other
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Gram-positive bacteria. Further studies will be necessary to uncover the mechanism of
resistance.
To determine the prevalence of metronidazole- and- vancomycin resistance in clinical
isolates of C. difficile from Texas and Kenya, the stool samples were analyzed using C.
difficile specific agar selective medium. The stool samples that contained C. difficile
strains resistant to either or both antibiotics were grouped into three categories, Met-R,
Van-R and Met-Van-R, and comprised of 33% of the Texas stool samples and
unexpectedly 93.7% of the Kenya stool samples. These prevalence rates significantly
exceed prior reports from other studies such as, the 2011 to 2014 longitudinal
surveillance report from the US and Europe, which reported a low percent of both
metronidazole and vancomycin resistance (28). The sudden increase in prevalence
could be a result of an unexplored potential link between CDI treatment failure and
antimicrobial resistance. CDI treatment failure has not been shown to have a
relationship with antimicrobial resistance (4). A reduced 8 µg/ml fecal concentration of
metronidazole may result in a simultaneous decrease of concentration that
accompanied reduction of colonic inflammation (4). This concentration is high enough to
kill susceptible C. difficile strains and low enough to be a sub-inhibitory concentration for
resistant strains so that it could play a role in selecting and sustaining colonies with a
gradually increase in their MICs (81). In addition, as the concentration decreases
following cessation of metronidazole treatment, persistent spores could germinate into
vegetative cells (4). What appears to be a gradual increase in the prevalence of
metronidazole and vancomycin resistance from the previous (28) to the present
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indicates gradual dissemination of both vancomycin and metronidazole resistant
isolates in the community.
One interesting finding from this study was that a greater number of the isolates were
metronidazole resistant than vancomycin resistant. Although considerable variation in
C. difficile resistance patterns has generally been observed, the percent of vancomycin
resistance has been shown to exceed metronidazole resistance in most previous
studies (30). However, in this study, the rate of metronidazole resistance exceeded that
of vancomycin: 29.2% metronidazole and 26% vancomycin resistant isolates in Texas
and 84.7% metronidazole and 67.3% vancomycin in the examined Kenya population.
Conversely, previous published reports showed that 3.6% of stools from CDI patients in
the US, contained C. difficile strains that are resistant to metronidazole and 17.9% to
vancomycin (77). Similarly, prevalence rates of 0.11% and 2.29% were reported for
metronidazole and vancomycin, respectively, in Europe (77). Another study also
reported that 94% of the C. difficile isolates collected from Iran were susceptible to
metronidazole at 2 μg/ml and only 5.3% were vancomycin resistant (84). However, a
study conducted in Israel reported 47% vancomycin and 18% metronidazole resistance
(88). Interestingly, one study here in Texas reported 13.3% metronidazole resistance
and 0% vancomycin resistance (89), which is consistent with our report, although no
vancomycin resistance was isolated. The variation in resistance is probably as a result
of geographical location, and local or national antibiotics treatment policies. It is
noteworthy that, the hypervirulent strain (RT) 027 was consistently isolated in most
metronidazole and vancomycin resistance studies (4, 30). Its emergence underscored
the potential importance of antimicrobial resistance in spreading of epidemic C. difficile
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clones. Eleven (11) out of twenty (20) resistant strains from a European antimicrobial
surveillance study were ribotype 027 (77).
To determine the predisposition of an isolate becoming resistant to either or both
antibiotics in the two populations studied, Pearson’s statistical analysis was employed.
The analysis indicated that there is a higher tendency for a C. difficile isolate to be
metronidazole resistant in Kenya than Texas. This may be as a result of frequent selfmedication with metronidazole that occurs in Kenya. Unexpectedly, the tendency for
vancomycin resistance is also higher in Kenya than Texas even though, there is no
significant vancomycin treatment of CDI in Kenya. Both metronidazole and vancomycin
resistance are more prevalent in Kenya than Texas. However, there was a greater
number of highly vancomycin resistant isolates in the Texas samples than those from
Kenya, suggesting that the reported inappropriate empirical treatment of CDI patients
who do not meet the criteria for severe CDI may be responsible (15).
To determine the level of antibiotic resistance in the isolated C. difficile strains, the Etest strip assay was used. Isolates from the three groups of resistance (Met-R, Van-R
and Met-Van-R) were represented. Most of the metronidazole sensitive isolates (3 out
of 4) became metronidazole resistant and even more (12 out of 15) vancomycin
sensitive became resistant. This unanticipated change from sensitive to resistant
suggests heterogenous resistance resulting from some C. difficile sensitive strains
expressing resistance after freeze-thawing of stored samples. Previous reports have
also shown a similar phenotypic change after frozen samples were thawed for analysis
(4, 90). Also, a slow-growing metronidazole resistant sub-population of C. difficile have
been observed after an extended incubation period of the E-test assay (4). This was
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also observed in our study. Sub-population of the isolates grew colonies inside the zone
of inhibition after a period.
To further confirm the E-test determined MICs of the resistant isolates and to determine
the MICs beyond the 256 µg/ml limit of the E-test strip used in this study, broth
microdilution method was used. Eighty (80%) and 41% of vancomycin resistant isolates
from Texas and Kenya, respectively, had vancomycin MIC >16 µg/ml, which is
significantly higher than the currently reported maximum MIC 16 µg/ml (30). Whereas
the proportion of the metronidazole resistant isolates with metronidazole MIC ˃ 256
µg/ml (78), was 97.8% and 86.6% for Texas and Kenya respectively. It was not
unexpected to isolate metronidazole-resistant isolates with significantly high MIC as
sub-inhibitory concentration of metronidazole measured in the colon (0.8 to 24.2 µg/g)
might play a role in selecting and sustaining colonies with a gradual increase in MICs
(81). However, similar MIC levels in vancomycin-resistant isolate was unanticipated as
the fecal concentration of vancomycin is high, range from 520 to 2200 µg/ml (82, 89).
The observed high MIC could also be because of horizontal gene transfer from other
Gram-positive bacteria possessing vancomycin resistance genes. The C. difficile
genome (11%) contains mobile genetic element that includes antibiotics resistant
genes. These could be transferred between different C. difficile strains or between C.
difficile and other bacteria (30,90). High level of resistance in vancomycin-resistant
Staphylococcus aureus was found to be a result of horizontal gene transfer from
coinfecting vancomycin-resistant Enterococcus (91).
The report of this study calls for attention to the significant percent of Texas and Kenyan
patients (95%) who may not respond to metronidazole treatment and 80% and 41% of
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Texas and Kenyan respectively, who may equally not respond to vancomycin treatment
(Fig. 8). These are the percent of C. difficile isolates from patient stool samples with
MICs higher than four times the currently prescribed dosage of metronidazole and
vancomycin which is the maximum concentration of antibiotics that will effectively clear
the bacteria from the system (93). The highest dosage of metronidazole currently
prescribed is 500 mg (91, 92) and 125 mg for vancomycin (92). Use of metronidazole
for long‐term chronic therapy or beyond the first recurrence of CDI is not recommended
because of its potential cumulative neurotoxicity (54). Nephrotoxicity is also a potential
serious side effect associated with high and prolong vancomycin therapy (92). As a
result, an increase in dosage or prolonged therapy with either of the antibiotics is greatly
discouraged.
No correlation between toxin production and the levels of resistance was observed for
the 20 isolates with different MICs selected from Texas and Kenya suggesting that
different pathways control toxin production and antibiotics resistance. However, no
measurable toxin production was recorded in the isolates that had grown poorly as it
has been shown that toxin production in C. difficile is quorum sensing regulated (12)
and so these experiments will be repeated with high level of growth for all the isolates.
In this study, the effect of sub-inhibitory concentrations of vancomycin on biofilm
formation showed no significant effect on the isolates with high resistance, intermediate
resistance, and low resistance. On the contrary, a similar study that tested the effect of
sub-inhibitory concentrations of metronidazole (not vancomycin) on biofilm formation
in C. difficile strains (79) revealed a significant increase in biofilm formation when
treated with metronidazole in the strains with reduced antibiotic susceptibility and
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susceptible strain but their stable-resistant strain had no change in biofilm formation
when the antibiotic was in the medium. Our experiment was performed using crystal
violet assay which has limitations and this result could be improved with a more
comprehensive assay.
The recognized genes for vancomycin resistance include vanA, B, and D that are
responsible for the biosynthesis D-alanine-D-lactate instead of the normal terminating
precursor D-alanine-D-alanine. Vancomycin-resistant E. faecalis and E. faecium that
possess vanA have been associated with inducible high level of resistance to
vancomycin (MICs, ≥64 μg/ml). Initially vanB was believed to induce modest levels of
vancomycin resistance (MICs, 32 to 64 μg/ml), however, recent reports revealed that
vanB gene may afford a maximum resistant up to ≥1000 μg/ml (122). vanC, E, G, and L
are responsible for D-alanine-D-serine biosynthesis instead of normal D-ala-D-alaterminating precursors and are associated with low-level vancomycin resistance. This
characterized low-level resistance to vancomycin have been found and well-studied in
Staphylococcus aureus and Enterococcus spp (30, 94). To date, no functional
vancomycin resistance genes have been identified in C. difficile (30). Since one of these
listed nine genes is always expressed (30) in vancomycin resistant in other Grampositive bacteria, we decided to perform a PCR analysis using PCR primers for the nine
genes to explore potential amplification of any of the genes in our isolates. Interesting,
the vanA primer successfully amplified the expected 800bp fragment in all the resistant
isolates tested. The vanA gene has been previously shown to mediate high level of
resistance to vancomycin and it is possible that the observed high level of resistance in
our isolates is related to the vanA gene.
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The vanA gene encodes the enzyme that synthesizes D-alanine-D-lactate and
functions in conjunction with three other enzymes Van H, X and Y. The mechanism is
well studied and defined in both Staphylococcus aureus and Enterococcus spp (30). To
begin our studies of the vancomycin resistance mechanism in C. difficile, we will first
attempt to identify the vanH X and Y genes in the genome of our vancomycin resistant
isolates either by PCR or whole genome sequencing. The mechanism of vancomycin
resistance may be different in the different C. difficile strains as a previous study has
shown the diversity in the genome of different strains of C. difficile. For instance, the
hypervirulent strain (R20291) that encode both accessory gene regulator (agr1 and
agr2) and the non-hypervirulent strain (630) encodes only agr1 (107).
Multiple studies have investigated the diversity in the genome of C. difficile, however,
this is the first time the vanA gene is identified in vancomycin-resistant C. difficile
isolates. The PCR products amplified using the primers were directly sequenced and
compared with vanA gene of E. faecieum, the observed differences in the 5’ end of the
sequence alignment strongly suggest poor amplification of some of the PCR products
resulting in poor sequence that impeded the data evaluation. As a result, the PCR
products were cloned into a vector, transformed and the clones were sequenced. They
gave better result (13).
In the future, the potential relationship between the degree of resistance and the colony
appearance (sizes or shape) will be explored. Each plate containing stool samples with
viable C. difficile colonies was analyzed and the different sizes and shapes of colonies
recorded. Some of the colonies possessed irregular, Webb-like shapes or smooth
edges. The study of colony morphology is important, as other studies have shown that
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the surface layer (S-layer), is responsible for bacteria adhesion to host cells and that a
mutation in one of the cysteine proteases involved in assembly of S-layer, resulted in
the inability to retain a specific cell wall protein leading to altered cell morphology (86).
Another study that compared an assay for selective and differential C. difficile isolation
from feces showed that colony size enables possible identification within 24 hours (87).
In summary, the data reported here, established the prevalence of metronidazole- andvancomycin resistance C. difficile isolates from Texas and Kenyan CDI patients,
determined the level of resistance of each of the isolates, reported a high vancomycin
MIC greater than the currently reported and suggest for the first time the mechanism
responsible for vancomycin resistance.

Summary and Perspective
The goal of the thesis was to establish the prevalence of metronidazole- and
vancomycin-resistance in C. difficile in two different populations and also to uncover the
potential resistance mechanisms involved. We isolated and characterized
metronidazole- and- vancomycin resistant isolates from stool samples from both Texas
and Kenya and analyzed their prevalence according to the location and the tendency of
acquiring each resistance with respect to location. C. difficile resistance to both
antibiotics is prevalent in both Texas and Kenya. Interestingly higher resistance to both
antibiotics is prevalent in Kenya.
Analysis of the degree of resistance of the isolates revealed relatively high MICs in the
two the populations. The two methods used for MIC determination (the E-test strip and
broth microdilution methods), were compared. The E-test method had an agreement of
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˃90% in comparison to broth microdilution method. There is a significantly high level of
metronidazole-resistance in both populations when compared to vancomycin. The
degree of vancomycin resistance is more spread across all levels of resistance although
a high proportion had a high degree of resistance with ˃256 µg/ml. On the other hand, a
relatively significant percent of metronidazole resistance isolates is highly resistant.
Three distinct groups were identified after MIC determination, the low resistance,
intermediate resistance, and high resistance. These three groups will be used for further
analysis. In the future, whole genome sequence analysis will allow a comparison
between the three groups and analysis of gene expression can also be used. This
analysis will help to uncover the resistance mechanism and possibly be useful in the
identification of a small molecule inhibitor as an alternative therapy.
Colonies were classified in order to explore potential relationship between the degrees
of resistance or etiology to the sizes of the different colonies. Viable colonies had
different sizes with some possessing irregular edges, Webb-like shapes and smooth
round edges. Further studies will explore these phenotypes. The study of colony
morphology is important, as other studies have shown that the surface layer (S-layer), is
responsible for bacteria adhesion to host cells and that a mutation in one of the cysteine
proteases involved in assembly of S-layer, resulted in the inability to retain a specific
cell wall protein leading to altered cell morphology (113). Another study that compared
an assay for selective and differential C. difficile isolation from feces showed that size of
colony enables possible identification within 24 hours (114).
Further analysis is required to examine the spore formation ability of the different
colonies, toxin production and explore their relationship with antibiotic resistance.
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Our hypothesis that sub-inhibitory concentration of vancomycin will induce more biofilm
formation in the reduced susceptible and intermediate isolates, but not high resistant
was proven false, although as expected, the high resistant isolates that may not need
biofilm as a defense mechanism in the presence of vancomycin had minimal biofilm
formation. Further analysis is recommended in the biofilm analysis with a more accurate
assay or technique.

Future Experiments
1. A study to isolate Enterococci species from the same stool samples containing C.
difficile isolates with high vancomycin-resistance in order to analyze and
compare the vanA gene is recommended.
2. VanA-type resistance is mediated by transposon Tn1546 (20). A whole genome
sequence analysis is recommended to determine if the same transposon also
mediates the vanA gene in C. difficile and to determine whether the resistance is
due to a genomic mutation or plasmid-encoded.
3. A detailed study of the pathway that mediates vanA resistance is suggested to
develop a novel target, such as small nonantibiotics molecules that will address
the high level of resistance.
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